In recent days, factor Xa (FXa) inhibitor attracts much attention as a promising drug candidate for anticoagulation.
FXa, a serine protease in the blood coagulation cascade, 4) is essential for the formation of thrombin. It plays an important role in the coagulation cascade at the convergent point of the intrinsic and the extrinsic pathway. FXa inhibitor is expected to be a novel antithrombotic with potential for the treatment and prevention of thromboembolic diseases. 5, 6) In previous papers, 7, 8) we reported the syntheses and FXa inhibitory activities of bisamidine compounds having indoline moiety in the center of the molecule. In these studies, we found that (R)-5-[1-(acetimidoyl)piperidin-4-yloxy]-2-(7-amidinonaphthalen-2-yl)-1-(ethanesulfonyl)indoline ((R)-1) and ({(R)-5-[1-(acetimidoyl)piperidin-4-yloxy]-2-(7-amidinonaphthalen-2-yl)indolin-1-yl}sulfonyl)acetic acid ((R)-2) exhibited potent FXa inhibitory activities (Fig. 1) . However, these compounds also exhibited potent inhibitory activities against trypsin which belongs to a serine protease family. In general, compounds having selective inhibitory activity against target enzyme were favorable as drug candidates because of less possibility of unexpected adverse reaction. From this viewpoint, we searched for a potent and selective FXa inhibitor.
Herein, we describe the synthesis and structure-activity relationships (SARs) and FXa selectivity of these compounds.
Chemistry
(E)-Substituted cinnamaldehyde intermediates 4a-e were synthesized as shown in Chart 1. 3-Cyanobenzaldehyde (3) was reacted with ylides to give corresponding substituted cinnamaldehyde 4a-c. Compound 3 and methyl acrylate (5) were coupled to give cinnamate 6d having a methoxymethyl group on the a-position. 3-Cyanoacetophenone (7) was reacted with an ylide to give cinnamate 6e having a methyl group on the b-position. Compounds 6d and 6e were converted to cinnamaldehydes 4d and 4e by 3 steps, respectively.
The syntheses of bisamidine derivatives (13a-e) are outlined in Chart 2. Cinnamaldehyde 4a-e were coupled with compound 8a 7) by tetrabutylammonium fluoride (TBAF) to give the corresponding alcohols 9a-e. 9) Nitro groups of alcohols 9a-e were converted to ethanesulfonylamino groups to give 11a-e. Intramolecular Mitsunobu reaction 10) of 11a-e with n-Bu 3 P and 1,1Ј-(azodicarbonyl)dipiperidine (ADDP) afforded 12a-e having indoline rings. 12a-e were converted to desired bisamidine derivatives 13a-e by 3 steps.
The syntheses of bisamidine derivatives (13f, 13g, 13i, 13j) are outlined in Chart 3. After reaction of aniline 10a with a sulfonyl chloride 11) or acyl chlorides, resulting sulfonamide 11f or amides 11g and 11h were cyclized by the same process described above to give indoline 12f-h. An acetoxy group of indoline 12h was hydrolyzed to give alcohol 12i. In a similar method described above, 12f, 12g and 12i were converted to desired bisamidine derivatives 13f, 13g and 13i, respectively. Carboxylic acid 13j was synthesized from ester 13f by acid hydrolysis.
The syntheses of bisamidine derivatives (13k-r, 13t, 13u) having substituents on aryl carbons of indoline are outlined in Chart 4. Substituted nitrophenols 14 were coupled with N-protected piperidinol 15, followed by reaction with (trimethylsilylmethyl)magnesium chloride to give the corresponding 2-substituted-3-trimethylsilylmethyl derivatives (8l, 8n, 8p, 8r) and/or 2-substituted-5-trimethylsilylmethyl derivatives (8k, 8m, 8o, 8q, 8s).
12) Compounds 8k-s were converted to cyclized compounds 12k-s by a similar method described in Chart 2. A 1,3-dioxolan-2-yl group of compound 12s was converted to a carboxyl group (12t) by 2 steps. Furthermore, 12t was converted to amide 12u in a standard manner. Cyclized compounds 12k-r, 12t and 12u were converted to desired bisamidine compounds 13k-r, 13t and 13u by a similar method described in Chart 2.
The syntheses of optically active (R)-13j and (S)-13j are outlined in Chart 5. After oxidation of racemic alcohol 9a, ketone 16 was subjected to enantioselective reduction 13, 14) by using chiral prolinol ligand (R)-17 or (S)-17, followed by reduction of a nitro group to give optically pure aniline (S)-10a and (R)-10a, respectively. Optically pure and stereochemically inversed bisamidines (R)-13j and (S)-13j were synthesized from (S) and (R)-10a by the same method as their racemate, respectively.
The syntheses of 5-amidino-2-hydroxycinnamyl derivatives (22a-c, 22f-h) are outlined in Chart 6. After treatment of compound 18 with ylide, a hydroxyl group of resulting compound 19 was protected to give O-protected cinnamaldehyde 20. Compound 20 was converted to cyclized compounds (21a, 21c, 21d, 21e) by a similar method described in Chart 2. A methoxymethyl group of 21a was converted to a methyl group by 3 steps to give compound 21b. Cyclized compounds 21a-e were converted to desired compounds 22a-e by a similar method described in Chart 2. Furthermore, carboxylic acids 22f-h were synthesized from the corresponding esters 22c-e by acid hydrolysis.
Results and Discussion
In vitro FXa and trypsin inhibitory activities of all compounds were evaluated and expressed as IC 50 values.
As described above, we considered that it is important not only to enhance FXa inhibitory activity but to improve selectivity over trypsin. From this viewpoint, we reexamined various moieties of the indoline compound we have reported previously. 7, 8) First, we focused on the naphthalene structure attached to an indoline ring (Table 1) . We synthesized a cinnamyl compound 13a, a ring-opening form of naphthalene, and tested its inhibitory activity against FXa and trypsin. Compound 13a exhibited potent FXa inhibitory activity even equal to naphthyl compound 1. Moreover, 13a exhibited 10-fold enhanced selectivity for FXa over trypsin. This selectivity was superior to that of naphthyl compound 1. According to this result, cinnamyl moiety seemed to be appropriate as an alter- native to naphthyl moiety. To optimize this moiety, substituents were introduced on the double bond and their effects were evaluated (Table 2 ). An introduction of a methyl or an ethyl group on the b-position of the cinnamyl moiety (13b, 13c) resulted in a decline of FXa inhibitory activity and selectivity compared to that of 13a. To examine the effect of an introduction of a polar substituent at this position, methoxymethylene compound 13d was synthesized and its inhibitory activity was evaluated. However, the activity was similar as those of 13b and 13c. On the other hand, compound 13e, having a methyl group on the a-position, exhibited much less inhibitory activity and selectivity. According to these results, a,b-non-substituted cinnamyl moiety seems to be more suitable.
Next, the effect of the substitution of the nitrogen atom of the indoline ring was examined ( Table 3) . Conversion of ethanesulfonyl moiety of 13a into sulfonylacetic acid (13j) and its ester form (13f) brought about similar FXa inhibitory activities as 13a, but as for 13j, selectivity over trypsin was improved. On the other hand, acetyl compound 13g showed slightly less FXa inhibitory activity. An introduction of a hydroxyl group on the acetyl moiety (13i) resulted in similar FXa inhibitory activity as 13a. However, 13i also exhibited potent inhibitory activity against trypsin. These results were also confirmed for the naphthylindoline derivatives, 8) and suggest that sulfonylacetic acid type structures are favorable at this position.
Furthermore, the effects of the substituents on the indoline ring (4-vs. 6-position) were examined (Table 4) . Compounds having a fluorine atom, a bioisoster of a hydrogen atom, on the 4-(13n) or 6-position (13m) resulted in the same result as non-substituted compound 13f. Compounds having a more bulky group than a hydrogen atom (13k, 13o, 13q, 13t, 13u ) at the 6-position exhibited potent inhibitory activities against both FXa and trypsin. On the other hand, compounds (13l, 13p, 13r) having a similar bulky group as above at the 4-position exhibited potent FXa inhibitory activity. Moreover, selectivity over trypsin was improved compared to that of 13f. These results suggest that an introduction at the 4-or 6-position does not have an influence against FXa inhibitory activity, but they do have a significant influence against trypsin inhibitory activity. Furthermore, the bulkiness was important for these activities, whereas the electron property (electron withdrawing/donating group) was not so important. From these results, it seemed that the 4-substitution is preferable to 6-substitution.
All compounds discussed above are racemates having an asymmetric carbon atom at the 2-position of the indoline ring. We previously reported that the (R)-naphthylindoline derivative exhibited over 20 times higher FXa inhibitory activity than the corresponding (S)-isomer. 7) Based on this result, each of the enantiomers ((R)-and (S)-13j) of a cinnamylindoline derivative 13j was prepared and their FXa and trypsin inhibitory activities were evaluated (Table 5) . However, to our surprise, the FXa inhibitory activities of (R)-and (S)-13j were nearly equal. We thought that this result was caused by the structural flexibility of cinnnamyl moiety. The structure of the cinnamyl group was less rigid than that of the naphthyl group, so it seemed that the difference of FXa inhibitory activity between (R)-and (S)-cinnamylindoline derivative was not observed. Moreover, from the synthetic aspect, selective synthesis of the one enantiomer needs more effort compared to that of its racemate. According to this result, we considered that it is suitable to develop our cinnamylindoline derivatives as a racemate. The effect of the substituents on the benzene ring of the cinnamyl moiety was examined (Table 6 ). Compound 22a, having a hydroxyl group at the 2-position, exhibited more potent FXa inhibitory activity and much higher selectivity over trypsin than non-substituted compound 13a. However, compound 22b, having a methoxy group on the same position, showed much lower inhibitory activity. This result suggests that the hydroxyl group on this position is highly important for both FXa inhibitory activity and selectivity over trypsin. From the X-ray crystallographic analysis, FXa has an amino acid residue Ser 195 in its S1 pocket 7, 15) and Ser 195 is located nearby the benzamidine moieties of FXa inhibitors. We speculate that the hydroxyl group at the 2-position of the benzene ring makes a hydrogen bond with Ser 195, whereas it makes a water-mediated hydrogen bond, a relatively indirect interaction, with Ser 195 in the S1 pocket of trypsin. [16] [17] [18] [19] It seems that this difference leads to both potent FXa inhibitory activity and the enzyme selectivity. On the other hand, the methoxy group of 22b makes it difficult to interact with the S1 pocket of both FXa and trypsin, so this caused a significant decline of inhibitory activity. Furthermore, the replacement of the ethanesulfonyl group by a carboxymethylsulfonyl group (and its ester form) gave the most potent FXa inhibitory activity (22a vs. 22f and 22c). Moreover, selectivity over trypsin of 22f was over 20 times improved compared to that of 13j. However, 22g and 22h with a chlorine atom at the 4-or 6-positon of the indoline ring exhibited, despite the result shown in Table 4 , lower FXa inhibitory activities than that of non-substituted compound 22f.
Compound 22f also exhibited good enzyme selectivity over other serine proteases (Table 7) . Therefore, compound 22f had the best profile in both the FXa inhibitory activity and enzyme selectivity among all compounds we have synthesized and tested.
We evaluated the anticoagulant activity of 22f on both prothrombin time (PT) and activated partial thromboplastin time (APTT) in human plasma (Table 8) . CT 2 values, the concentration required to achieve 200% relative clotting time, of 22f were 0.39 mM (PT) and 0.34 mM (APTT), whereas those of naphthyl compound (R)-2 were 0.48 mM (PT) and 1.2 mM (APTT), respectively. These results indicate that compound 22f has more potent in vitro anticoagulant activity than (R)-2.
In conclusion, we synthesized many cinnamylindoline derivatives to find compounds having potent FXa inhibitory activities and selectivity over trypsin. As a result, we found that some novel derivatives having 2-hydroxycinnnamyl moieties showed high FXa inhibitory activities and selectivity over trypsin. Among them, (E)-2-{5-[1-(acetimidoyl)piperidin-4-yloxy]-2-[2-(5-amidino-2-hydroxyphenyl)ethen-1-yl]indolin-1-ylsulfonyl}acetic acid (22f) exhibited potent FXa inhibitory activity and good enzyme selectivity in vitro. Furthermore, compound 22f exhibited potent in vitro anticoagulant activity in human plasma, although oral anticoagulant activity remains to be determined. Our further synthetic efforts are in progress and the results will be disclosed in the next report. 1498 Vol. 55, No. 10 Methyl (E)-3-(3-Cyanophenyl)-2-(methoxymethyl)-2-propenoate (6d) To a suspension of NaH (680 mg, 15.6 mmol, as a 55% w/w dispersion in mineral oil) in THF (15 ml) was added MeOH (0.730 ml, 18.0 mmol) at 0°C and the mixture was stirred at room temperature for 30 min. 3-Cyanobenzaldehyde 3 (1.31 g, 9.99 mmol) and methyl acrylate 5 (1.35 ml, 15.0 mmol) in THF (15 ml) was then added at 0°C and the mixture was stirred at room temperature for 2 h. The mixture was concentrated and the resulting residue 
Ethyl (E)-3-(3-Cyanophenyl)-3-methylacrylate (6e)
A solution of 3-cyanoacetophenone 7 (2.90 g, 20.0 mmol) and (carbethoxymethylene)triphenylphosphorane (17.4 g, 49.9 mmol) in xylene (150 ml) was refluxed for 4 h with stirring and the mixture was concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ4/1) to give 6e (1.61 g, 7.48 mmol, 37%) as a yellow solid. (E)-3-(3-Cyanophenyl)-2-(methoxymethyl)-2-propenal (4d) To a solution of methyl (E)-3-(3-cyanophenyl)-2-(methoxymethyl)-2-propenoate 6d (2.01 g, 8.69 mmol) in CH 2 Cl 2 (20 ml) and hexane (50 ml) was added diisobutylaluminum hydride (DIBAL) (1.5 M in toluene, 6.70 ml, 10.1 mmol) and i-Bu 3 Al (1.0 M in hexane, 10.0 ml, 10.0 mmol) at Ϫ78°C and the mixture was stirred for 30 min. After adding DIBAL (1.5 M in toluene, 6.70 ml, 10.1 mmol) and i-Bu 3 Al (1.0 M in hexane, 10.0 ml, 10.0 mmol) at Ϫ78°C and the mixture was stirred for 30 min. MeOH was added, and the mixture was diluted with EtOAc and washed with 1 N HCl, H 2 O, NaHCO 3 solution, and brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ1/1) to give a mixture of (E)-and (Z)-3-(3-formylphenyl)-2-(methoxymethyl)-2-propen-1-ol. The mixture was dissolved in 1-methyl-2-pyrrolidinone (30 ml) and the solution was added hydroxylamine hydrochloride (700 mg, 10.1 mmol). The mixture was stirred at 120°C for 4 h. After cooling, the mixture was diluted with EtOAc and washed with H 2 O, brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ1/1) to give (Z)-3-(3-cyanophenyl)-2-(methoxymethyl)-2-propen-1-ol (850 mg, 4.18 mmol) as a yellow solid. To a solution of (Z)-3-(3-cyanophenyl)-2-(methoxymethyl)-2-propen-1-ol (850 mg, 4.18 mmol) in CH 2 Cl 2 (10 ml) and hexane (10 ml) was added MnO 2 (5.00 g, 63.3 mmol) and the mixture was stirred at room temperature for 4 h. After adding MnO 2 (5.00 g, 63.3 mmol) and the mixture was stirred at room temperature for 1 h. MnO 2 was filtered away, and the filtrate was concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ3/2) to give 4d (0.71 g, 3.53 mmol, 41%) as a pale yellow solid. 1 
t-Butyl (E)-4-{3-[4-(3-Cyanophenyl)-2-hydroxy-3-buten-1-yl]-4-nitrophenoxy}piperidine-1-carboxylate (9a)
To a solution of (E)-3-cyanocinnamaldehyde 4a (1.00 g, 6.36 mmol) and t-butyl 4-[4-nitro-3-(trimethylsilylmethyl)phenoxy]piperidine-1-carboxlate 8a (2.86 g, 7.00 mmol) in THF (50 ml) was added a solution of TBAF monohydrate (0.180 g, 0.644 mmol) in THF (10 ml) at Ϫ10°C and the mixture was stirred at Ϫ10°C for 1 h. TBAF (75% in H 2 O, 1.19 g, 6.07 mmol) in THF (10 ml) was then added and the mixture was stirred at Ϫ10°C for 1 h. NH 4 Cl solution was added, and the mixture was extracted with EtOAc. The organic layer was washed with brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ1/1) to give 9a (2.59 g, 5.25 mmol, 82%) as a pale yellow amorphous solid. 05 mmol) in AcOH (25 ml) was added zinc powder (1.98 g, 30.3 mmol) and the mixture was stirred at room temperature for 1 h. The mixture was filtered, and the filtrate was concentrated. The resulting residue was diluted with EtOAc and washed with NaHCO 3 solution and brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ1/3) to give 10a (1.39 g, 3.00 mmol, 59%) as a brown oil. 98 mmol) in CH 2 Cl 2 (15 ml) was added EtSO 2 Cl (0.340 ml, 3.59 mmol) and pyridine (0.290 ml, 3.59 mmol) and the mixture was stirred at room temperature for 4 h. H 2 O was added, and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/ EtOAcϭ1/1) to give 11a (1.26 g, 2.27 mmol, 76%) as a yellow oil.
1 H-NMR -1-carboxylate 11a (1.20 g, 2. 16 mmol) in THF (30 ml) was added n-Bu 3 P (0.770 ml, 3.09 mmol) and ADDP (0.710 g, 2.81 mmol) in THF (10 ml) and the mixture was stirred at room temperature for 3 h. NH 4 Cl solution was added, and the mixture was extracted with EtOAc. The organic layer was washed with brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ11/9) to give 12a (1.05 g, 1.95 mmol, 90%) as a colorless amorphous solid. 50 g, 3 .24 mmol) in CH 2 Cl 2 (25 ml) was added ethoxycarbonylmethylsulfonyl chloride (664 mg, 3.56 mmol) in CH 2 Cl 2 (10 ml) at Ϫ10°C and the mixture was stirred for 1 h. Pyridine (0.290 ml, 3.59 mmol) was added, and the mixture was stirred for 1.5 h. Ethoxycarbonylmethylsulfonyl chloride (664 mg, 3.56 mmol) in CH 2 Cl 2 (2 ml) was added, and the mixture was stirred for 0.5 h. NaHCO 3 solution was added, and the mixture was extracted with CH 2 Cl 2 . The organic layer was washed with brine. The organic layer was dried and concentrated. The resulting residue was chromatographed on a silica gel column (hexane/EtOAcϭ1/1) to give 11f (576 mg, 0.938 mmol, 29%) as a yellow oil. 1 
